bluebird bio opens state-of-the-art gene and cell therapy manufacturing facility in Durham
bluebird bio announced the official opening of its first wholly owned manufacturing facility in Durham, N.C., that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for treatment of multiple myeloma. March 22, 2019